NFE2L2 and neoplasm: This supported the finding that PD-L1 expression in LUSC tumor cells was associated with NFE2L2 mutations [61] and indicated that LUSC patients carrying NFE2L2 mutations may be more responsive to anti-PD-L1 immunotherapy.